Esperion Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative, oral, once-daily, non-statin therapies for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C) and high cardiovascular risk. The company's primary commercial franchise is built around bempedoic acid, marketed in the United States as NEXLETOL and NEXLIZET (a combination of bempedoic acid and ezetimibe). Bempedoic acid acts as an ATP Citrate Lyase (ACL) inhibitor, lowering cholesterol biosynthesis and up-regulating LDL receptors. Internationally, Esperion commercializes its products through strategic partnerships, notably with Daiichi Sankyo Europe (DSE) in Europe and Otsuka Pharmaceutical in Japan.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A long-term strategic roadmap aimed at transforming Esperion into a multi-product, sustainable, innovation-driven global pharmaceutical company. The strategy focuses on expanding the core cardiometabolic franchise, advancing the pipeline into rare hepatic and renal diseases, and establishing multiple blockbuster products on the market by 2040.
Expected impact: Aims to establish sustainable profitability, diversify the product portfolio beyond the core bempedoic acid franchise, and drive long-term double-digit revenue growth.
Expanding the global footprint of the bempedoic acid franchise (NEXLETOL/NEXLIZET) through strategic collaborations with international partners, including Daiichi Sankyo in Europe, Otsuka Pharmaceutical in Japan, HLS Therapeutics in Canada, Neopharm in Israel, and CSL Seqirus in Australia.
Expected impact: Generates high-margin royalty streams and milestone payments, expanding the global patient reach of Esperion's therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Enbumyst (bumetanide nasal spray), the first and only FDA-approved intranasal loop diuretic, expanding Esperion's cardiovascular and cardiometabolic portfolio into outpatient fluid management for edema associated with congestive heart failure, hepatic disease, and renal disease.
Financial impact: Esperion paid $75 million upfront, with up to $180 million in potential regulatory and commercial milestones, plus low double-digit royalties on future global sales. The acquisition was funded through existing credit facilities and the monetization of Japanese royalties.
Strategic Partnerships
Otsuka manages the development, regulatory approval, and commercialization of bempedoic acid and its combination with ezetimibe in Japan, which is the third-largest global market for cardiovascular prevention.
Terms: Total agreement value of up to $600 million, including milestones and development costs, plus significant royalties on net sales. Esperion received a $90 million milestone payment in Q4 2025 following regulatory approval and NHI price listing in Japan.
DSE holds exclusive commercialization rights to Nilemdo and Nustendi in the European Economic Area, UK, Turkey, Switzerland, and other select territories, driving consistent double-digit annual growth across key European markets.
Terms: Generates ongoing royalty revenue and milestone payments based on regional sales performance.